S-Hydroxychloroquine Isomer Segmentation for APS Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for antiphospholipid syndrome (APS) such as Warfarin pose significant bleeding risks and long-term hydroxychloroquine (HCQ) administration can cause vision impairment and cardiotoxicity, necessitating a safer therapeutic option.
Innovation Solution
A method involving the administration of a pharmaceutical composition containing high-purity S-(+)-hydroxychloroquine (S-HCQ) and a pharmaceutically acceptable excipient, substantially free of the (R)-(−)-isomer, in various forms and doses, to treat APS effectively while minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Warfarin is used to treat APS-associated thrombosis, then the risk of blood clots is reduced, but the risk of bleeding complications increases significantly
Solution Approach 1:
The invention segments the HCQ molecule into its two optical isomers (R-HCQ and S-HCQ) and identifies that only the S-HCQ isomer provides therapeutic benefit for APS. By isolating and administering only the effective S-HCQ isomer rather than the racemic mixture, the treatment achieves thrombosis prevention while eliminating the cardiotoxic effects associated with R-HCQ, thus resolving the contradiction between efficacy and safety
Solution Approach 2:
The invention applies local quality by distinguishing between the different properties of the two HCQ isomers. The S-HCQ isomer possesses the desired therapeutic quality for APS treatment, while the R-HCQ isomer exhibits harmful cardiotoxic qualities. By selectively administering only the S-HCQ isomer with the appropriate therapeutic quality, the treatment achieves effective thrombosis prevention without the harmful bleeding and cardiac side effects
2Reliability
If long-term and high-dose HCQ is administered to treat APS, then the extent of thrombosis is reduced, but vision impairment and cardiotoxicity occur
Solution Approach 1:
The invention extracts the harmful R-HCQ isomer from the racemic HCQ mixture and administers only the beneficial S-HCQ isomer. This extraction of the harmful component eliminates the vision impairment and cardiotoxicity side effects while preserving the therapeutic effect on thrombosis, thereby resolving the contradiction between treatment efficacy and safety
Solution Approach 2:
The invention changes the chemical parameter of the HCQ administration by using pure S-HCQ isomer instead of the racemic mixture. This parameter change from a 50:50 mixture to pure enantiomer form maintains the therapeutic effect on thrombosis while eliminating the cardiotoxic and ocular side effects associated with long-term HCQ use
3Reliability
If racemic HCQ mixture is used for APS treatment, then thrombosis extent is reduced, but cardiotoxicity and vision impairment occur due to R-HCQ accumulation
Solution Approach 1:
The invention segments the racemic HCQ mixture into its two constituent isomers and identifies that only S-HCQ provides therapeutic benefit. By administering pure S-HCQ instead of the racemic mixture, the treatment achieves effective thrombosis management while eliminating the cardiotoxic and ocular harmful factors generated by R-HCQ accumulation
Solution Approach 2:
The invention converts the harmful racemic mixture into a beneficial pure enantiomer formulation. By separating and administering only the beneficial S-HCQ isomer, the treatment transforms the originally harmful racemic mixture (which causes cardiotoxicity and vision impairment) into a safe and effective therapy that maintains thrombosis treatment benefits without the harmful effects
Data Source
AI summary
A method for treating antiphospholipid syndrome by administering to a patient a pharmaceutical composition that contains S-(+)-hydroxychloroquine and a pharmaceutically acceptable excipient. The pharmaceutical composition is substantially free of R-(−)-hydroxychloroquine.